Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn’t hit its main goal. Post navigation Previous Previous post: Nancy Pelosi calls female US president in her lifetime unlikely: ‘Marble ceiling’Next Next post: Europe’s housing costs akin to ‘new pandemic’, warns Barcelona mayor Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Related News NVIDIA releases new Game Ready and Studio drivers with CUDA 13.3 support 0 4 Toyota Grand Highlander Hidden Features You May Not Have Noticed 0
